Cellectis Plans Q2 2025 Financial Results Release
In recent announcements, Cellectis, a pioneering clinical-stage biotechnology firm known for its innovative gene-editing platform, has shared its plans to report financial results for the second quarter of 2025. The report, covering the period ending June 30, is scheduled for release on August 4, 2025, soon after the closing of the U.S. financial markets. This exciting news reflects Cellectis' commitment to providing timely updates to its stakeholders.
Details of Upcoming Investor Call
Following the financial report, Cellectis will host an investor conference call scheduled for August 5, 2025, at 8:00 AM ET. This call aims to provide investors and analysts with insights into the company’s quarterly results and share updates on ongoing business activities. With the rapidly evolving landscape of biotechnology, this call is particularly significant for stakeholders interested in Cellectis’ advancements.
How to Join the Investor Call
Investors can participate in this important call by dialing in using the following numbers. Domestic participants can reach out at +1-800-343-5172, while international participants can connect using +1-203-518-9856.
For ease of access, a specific conference ID, CLLSQ2, will be required for joining the call. This structured approach ensures smooth communication during the event.
About Cellectis and Its Mission
Cellectis stands out in the biotechnology realm by leveraging its advanced gene-editing platform to develop crucial cell and gene therapies. The company has adopted an allogeneic method for CAR T therapies in oncology, revolutionizing treatment options for cancer patients. By offering off-the-shelf gene-edited CAR T-cells, Cellectis is at the forefront of changing how cancer is treated.
One of the company's distinguishing features is its in-house manufacturing capabilities, allowing it to handle the entire value chain of cell and gene therapy development. This end-to-end control positions Cellectis uniquely in the competitive landscape of gene editing and therapy development.
Company Locations and Market Presence
Cellectis has its headquarters in Paris, France, and operates additional locations in New York and Raleigh, NC. The company’s presence in two major markets enhances its position for growth and development in the field of biotechnology. Cellectis is publicly traded on both the Nasdaq Global Market under the ticker CLLS and on Euronext Growth with the ticker ALCLS.
Connecting with Cellectis
For those seeking more information about Cellectis’ initiatives, their official website offers extensive resources. Interested parties can also follow the company on professional networks like LinkedIn or updates on social media platforms to stay informed about their progress and announcements.
Contact Information for Further Queries
For media inquiries, the dedicated contacts at Cellectis include Pascalyne Wilson, Director of Communications, who can be reached at +33 (0)7 76 99 14 33. For investor relations, Arthur Stril, the Chief Financial Officer & Chief Business Officer, is available, further emphasizing the company's openness to engaging with its stakeholders regarding business-related queries.
Frequently Asked Questions
When will Cellectis announce its Q2 2025 financial results?
Cellectis will announce its financial results for the second quarter of 2025 on August 4, 2025.
What time is the investor call scheduled?
The investor conference call will take place on August 5, 2025, at 8:00 AM ET.
How can I join the investor call?
To join the call, dial +1-800-343-5172 for domestic calls or +1-203-518-9856 for international calls, using the conference ID CLLSQ2.
What is the focus of Cellectis as a biotechnology company?
Cellectis focuses on developing life-saving cell and gene therapies through its gene-editing platform.
Where is Cellectis headquartered?
The company’s headquarters is located in Paris, France, with facilities in New York and Raleigh, NC.
